The FDA on March 23, 2017 granted accelerated approval to BAVENCIO® for the treatment of patients 12 years and older with metastatic Merkel Cell Carcinoma (MCC). BAVENCIO® is a programmed death-ligand 1 (PD-L1) blocking human IgG1 lambda monoclonal antibody. This is the first FDA-approved product to treat this type of cancer. BAVENCIO® is a marketed by EMD Serono, Inc.
Bottom Ad
Advertisement
Subscribe
